SMARCA4 and neoplasm: For instance, loss-of-function mutations of BRG1 are found in about 30% of NSCLC cell lines, with approximately 10% of NSCLC tumors confirmed to exhibit BRG1 inactivating mutations, suggesting a tumor suppressor role [55].